Kbc Group Nv Vir Biotechnology, Inc. Transaction History

Kbc Group Nv

$36.3 Billion
Q4 2024

A detailed history of Kbc Group Nv transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 8,970 shares of VIR stock, worth $94,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,970

Previous 3,793 136.49%

Holding current value

$94,454

Previous $28,000 135.71%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 22, 2025	BUY	$6.74 - $10.17 $34,892 - $52,650	5,177 Added 136.49%	8,970 $66,000
Q2 2024 Jul 17, 2024	BUY	$7.63 - $12.66 $9,720 - $16,128	1,274 Added 50.58%	3,793 $34,000
Q4 2023 Feb 13, 2024	SELL	$7.76 - $10.29 $23,124 - $30,664	-2,980 Reduced 54.19%	2,519 $25,000
Q3 2023 Feb 15, 2024	SELL	$9.14 - $24.62 $27,237 - $73,367	-2,980 Reduced 54.19%	2,519 $24,000
Q2 2023 Feb 15, 2024	SELL	$23.2 - $27.29 $27,932 - $32,857	-1,204 Reduced 17.96%	5,499 $135,000
Q2 2023 Jul 28, 2023	SELL	$23.2 - $27.29 $13,618 - $16,019	-587 Reduced 9.65%	5,499 $135,000
Q1 2023 Feb 14, 2024	SELL	$22.26 - $30.85 $13,734 - $19,034	-617 Reduced 9.2%	6,086 $142,000
Q1 2023 May 04, 2023	SELL	$22.26 - $30.85 $13,734 - $19,034	-617 Reduced 9.2%	6,086 $142,000
Q3 2022 Feb 15, 2024	BUY	$18.26 - $31.1 $76,399 - $130,122	4,184 Added 166.1%	6,703 $129,000
Q2 2022 Feb 14, 2024	BUY	$19.08 - $26.7 $79,830 - $111,712	4,184 Added 166.1%	6,703 $171,000
Q2 2022 Jul 26, 2022	BUY	$19.08 - $26.7 $127,893 - $178,970	6,703 New	6,703 $171,000

Others Institutions Holding VIR

# of Institutions

214

Shares Held

86.6M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.4B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account